Amlodipine Recall

Get an alert when a recall is issued.

Questions & Answers

Side Effects & Adverse Reactions

There is currently no warning information available for this product. We apologize for any inconvenience.

Legal Issues

There is currently no legal information available for this drug.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.


Amlodipine, valsartan and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including amlodipine, hydrochlorothiazide, and the ARB class to which valsartan principally belongs. There are no controlled trials demonstrating risk reduction with amlodipine, valsartan and hydrochlorothiazide tablets.

Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).

Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.

Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (e.g., patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.

Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.

This fixed combination drug is not indicated for the initial therapy of hypertension [see Dosage and Administration (2)].


There is currently no drug history available for this drug.

Other Information

Amlodipine, valsartan, and hydrochlorothiazide tablets are fixed combination of amlodipine, valsartan and hydrochlorothiazide.

Amlodipine, valsartan and hydrochlorothiazide tablets contain the besylate salt of amlodipine, a dihydropyridine calcium channel blocker (CCB). Amlodipine besylate, USP is a white to pale yellow crystalline powder, slightly soluble in water and sparingly soluble in ethanol. Amlodipine besylate's chemical name is 3-Ethyl 5-methyl (±)-2-[(2-aminoethoxy)methyl] -4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate, monobenzenesulfonate; its structural formula is:

Image 1

Its empirical formula is C20H25ClN2O5•C6H6O3S and its molecular weight is 567.1.  

Valsartan, USP is a nonpeptide, orally active, and specific angiotensin II antagonist acting on the AT1 receptor subtype. Valsartan, USP is a white to practically white fine powder, soluble in ethanol and methanol and slightly soluble in water. Valsartan's chemical name is N-(1-oxopentyl)-N-[[2′-(1H-tetrazol-5-yl) [1,1′-biphenyl]-4 -yl]methyl]-L-valine; its structural formula is: 

image 2

Its empirical formula is C24H29N5O3 and its molecular weight is 435.5. 

Hydrochlorothiazide, USP is a white, or practically white, practically odorless, crystalline powder. It is slightly soluble in water; freely soluble in sodium hydroxide solution, in n-butylamine, and in dimethylformamide; sparingly soluble in methanol; and insoluble in ether, in chloroform, and in dilute mineral acids. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide.  

Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C7H8ClN3O4S2, its molecular weight is 297.73, and its structural formula is:

Image 3

Amlodipine, valsartan and hydrochlorothiazide film-coated tablets are formulated in 5 strengths for oral administration with a combination of amlodipine besylate, valsartan, and hydrochlorothiazide, providing for the following available combinations: 5/160/12.5 mg, 5/160/25 mg, 10/160/12.5 mg, 10/160/25 mg, and 10/320/25 mg amlodipine/ valsartan/hydrochlorothiazide. The inactive ingredients for all strengths of the tablets include croscarmellose sodium, hypromellose, magnesium stearate, mannitol, polyethylene glycol, povidone, talc and titanium dioxide. Additionally, the 5/160/25 mg, 10/160/12.5 mg, 10/160/25 mg and 10/320/25 mg strengths contain ferric oxide yellow.

Amlodipine Manufacturers

  • Torrent Pharmaceuticals Limited
    Amlodipine, Valsartan And Hydrochlorothiazide Tablet [Torrent Pharmaceuticals Limited]
  • Par Pharmaceutical Inc.
    Amlodipine, Valsartan, Hydrochlorothiazide (Amlodipine Besylate Valsartan Hydrochlorothiazide) Tablet, Film Coated [Par Pharmaceutical Inc.]
  • Sandoz Inc
    Amlodipine, Valsartan, Hydrochlorothiazide (Amlodipine Valsartan And Hydrochlorothiazide) Tablet, Film Coated [Sandoz Inc]
  • Teva Pharmaceuticals Usa Inc
    Amlodipine, Valsartan, And Hydrochlorothiazide Tablet, Film Coated [Teva Pharmaceuticals Usa Inc]
  • Caraco Pharmaceutical Laboratories, Ltd.
    Amlodipine (Amlodipine Besylate) Tablet [Caraco Pharmaceutical Laboratories, Ltd.]
  • Remedyrepack Inc.
    Amlodipine Tablet [Remedyrepack Inc. ]
  • Macleods Pharmaceuticals Limited
    Amlodipine (Amlodipine ) Tablet [Macleods Pharmaceuticals Limited]
  • State Of Florida Doh Central Pharmacy
    Amlodipine (Amlodipine Besylate) Tablet [State Of Florida Doh Central Pharmacy]

Login To Your Free Account